| news from Auxilium |
|
|
1
|
| 1
|
|
12/20/2005 23:20
Wolfgang Wachnot registered
|
12/20/2005 23:20
Wolfgang Wachnot registered
|
news from Auxilium
I failed accessing the news story, therefore I had a look at the Auxilium web site. Auxilium describes AA4500 as a therapy for IPP (Peyronie) but does not mention Dupuytren (though it is mentioned on the Cobra site). If AA4500 works for Dupuytren why don't they mention it? That would be the bigger market.
Does anyone know more details about AA4500? I haven't found any research papers on AA4500. In August 2005 Auxilium stated "We feel confident that Cobra will deliver us quality AA4500 for our Phase II/ III clinical trials." Are they still into phase II? What is the mechanism, what are potential side effects of AA4500?
Wolfgang
|
|
|
|
|
12/20/2005 23:31
jim hnot registered
|
12/20/2005 23:31
jim hnot registered
|
forget about it
The only PR release from Auxilium on December 20th is the one about their buying the rights, from BSTC, to market AA4500 for frozen shoulder. They already have the rights for Dupyuytren's and Peyronie's.
This announcement is just more PR fluff and doesn't indicate any actual progress in getting the drug to market.
I've long since given up on Collagenase/Cordase/AA4500, or whatever they rename it next year. It's just an endless financial game where 'rights' are acquired on speculation, millions of investment dollars are pulled in and trials are perpetually just a few months away.
|
|
|
|
|
|
1
|
| 1
|
325 users online
Login
